Zometa
08 »
Zometa
Zoledronic acidSystematic (IUPAC) name(1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acidIdentifiersCAS number118072-93-8ATC codeM05BA08PubChem68740DrugBankAPRD01294Chemical dataFormulaC5H10N2O7P2 Mol. mass272.09 g/molPharmacokinetic dataBioavailability ?Protein binding22%MetabolismNilHalf life146 hoursExcretionRenal (partial)Therapeutic considerationsLicence dataEU EMEA:link, US FDA:linkPregnancy cat.D (U.S.)Legal status℞-only (U.S.)RoutesIntravenousZoledronic acid (INN) or zoledronate (marketed by Novartis under the trade names Zometa, Zomera, Aclasta and Reclast) is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases.An annual dose of zoledrinic acid may also prevent recurring fractures in patients with a previous hip fracture.Reclast is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.// AdministrationThe standard dose for zoledronate is 4 mg to be infused intravenously over 15 min every 3–4 weeks in cancer patients. For Reclast a single dose of 5 mg is used for the treatment of Paget's disease.Zoledronate has been approved as a once-yearly 5 mg infusion for treatment of osteoporosis and shown significant benefits versus placebo over three years, with a reduced number of vertebral fractures and improved markers of bone density. Side effectsSide effects can include fatigue, anemia, muscle aches, fever, and/or swelling in the feet or legs. Flu-like symptoms are commonly experienced after the first zoledronate infusion, although not subsequent infusions, and are thought to occur because of its potential to activate human γδ T cells.Zoledronate is rapidly processed via the kidneys; consequently its administration is not recommended for patients with reduced renal function or kidney disease.A rare complication that has been recently observed in cancer patients being treated with bisphosphonates is osteonecrosis of the jaw. This has mainly been seen in patients with multiple myeloma treated with zoledronate who have had dental extractions. ContraindicationsPoor renal function (e.g. creatinine>3 mg/dL)PregnancyParalysis
.Women who were given the drug, Zometa, as part of their initial treatment had greater tumor shrinkage and were less likely to need radical surgery, according to a preliminary study reported Thursday at a cancer conference in Texas.Bone drug Zometa might help fight breast cancer while given with chemo, study reportsNew research adds fresh hope that a drug that strengthens bones might also fight breast cancer.Michele explains the side effects of Zometa, a popular breast
Even more about Zometa
Zometa
Learn how ZOMETA (zoledronic acid) helps prevent skeletal-related events (SREs) in patients with advanced malignancies involving bone metastases.
Zometa (zoledronic Acid) for patients with malignancies involving bone ...
When cancer has spread to the bone, treatment with ZOMETA may reduce or delay bone complications. Learn more about how ZOMETA can help.
Zometa (zoledronic acid) Therapy, Cancer and the Bones, and Bone ...
ZOMETA is an FDA-approved prescription drug developed by Novartis Oncology. It is used to treat cancers including breast lung, and prostate cancer that have spread to the bones a ...
Zometa (zoledronic acid) Therapy and Bone Metastases (Mets)
Produktinformation & Fachinformation Zometa ... Zometa ® Zometa ist das erste und einzige Bisphosphonat, das bei einer Vielzahl von soliden Tumoren wirksam Knochenkomplikationen ...
Novartis Pharma Österreich: Zometa Produktprofil
Keep up to date on Zometa s most recent published findings. This page is updated regularly.
Comment:
